Articles tagged with Cell Therapies
Researchers at the University of Colorado Cancer Center have made a breakthrough in treating pancreatic cancer by combining radiation and immunotherapy. The treatment eradicates tumors while stopping the cancer from spreading, offering new hope for patients. Clinical trials are planned to further develop this therapy.
Rice University scientists developed a screening technique to identify high-performing biomaterials for encapsulating insulin-secreting cells, providing long-term blood sugar level control in diabetic mice. The study's findings have the potential to open the door to a more sustainable and self-regulating way to treat Type 1 diabetes.
Researchers at Michigan State University have developed a gene therapy that successfully treats a form of progressive retinal atrophy in dogs with an inherited eye disease. The therapy is now being prepared for human clinical trials to treat retinitis pigmentosa, a rare genetic disorder causing vision loss.
A novel cell signaling pathway has been identified that could be targeted to treat aggressive pancreatic cancers. The High Mobility Group A1 (HMGA1) protein functions as a 'molecular switch' that activates genes required for tumor growth and invasion. Silencing HMGA1 or disrupting FGF19 signals in mouse models resulted in decreased tum...
A cell therapy using myeloid cells bound to drug delivery microparticles reduces disease burden in a preclinical multiple sclerosis model. The therapy partially reverses hind limb paralysis and improves motor functions.
Researchers have identified a new cell state in embryonic airway development, which may lead to new approaches for treating chronic respiratory diseases. The discovery highlights the crucial role of cellular heterogeneity in shaping airway biology.
Researchers developed an optimized genome-editing method that vastly reduces mutations, enabling more effective treatment of genetic diseases. The new technique uses a 'safeguard gRNA' to control DNA cleavage, reducing off-target effects and cytotoxicity.
Enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body. The drug targets B7-H3 protein overexpressed on prostate cancer cells, blocking immune system inhibition and triggering tumor cell destruction by activating immune cells.
Cancer-associated fibroblasts (CAFs) are a type of cell that plays a crucial role in the tumor microenvironment. The authors suggest that understanding CAFs is essential for developing effective cancer therapies. Research targeting CAFs has shown promise, but challenges remain due to their complex nature.
Research suggests that high doses of sucralose can lower activation of T-cells, an important component of the immune system, in mice. This finding could lead to a new way of using sucralose therapeutically to help dampen T-cell responses in patients with autoimmune diseases.
A WPI-led team used computational modeling to create a detailed picture of the SARS-COV-2 virus envelope, revealing its elliptical shape and changing structure. This discovery could lead to more effective therapies and vaccines, as well as a better understanding of the virus's properties.
The study found that downregulation of angulin-1/LSR leads to increased claudin-2 expression and altered cell metabolism in human lung adenocarcinoma cells, promoting malignancy. Researchers identified AG1478 and EW-7197 as potential therapeutic agents.
Researchers at Georgia Institute of Technology developed a synthetic tumor model to understand the impact of microenvironment on targeted therapies for Activated B Cell-like Diffuse Large B cell lymphoma. The model showed promise in demonstrating how combining therapeutics can overcome tumor resistance to inhibitors.
Researchers found significant decreases in the levels of KRAS, RHOA, RAC1, and CDC42 after PCAI treatment, implicating their role in cancer progression and metastasis. These findings support the potential of PCAIs as potent agents for developing new anticancer therapeutics.
Researchers have found that valosin-containing protein (VCP) is essential for KRAS-mutant pancreatic ductal adenocarcinoma cell growth and survival. Inhibiting VCP, combined with autophagy inhibition, enhances efficacy in preclinical studies.
Scientists have identified a new molecule that could help distinguish and treat patients with a specific subgroup of medulloblastoma, the most common malignant brain tumor in children. The discovery points to potential targeted therapies using a drug or drugs to block the molecule's activity.
Researchers at Mayo Clinic have made significant progress in treating multiple myeloma using chimeric antigen receptor therapy (CAR-T cell therapy), which has shown a median progression-free survival of 13.3 months compared to 4.4 months for standard treatment regimens.
Researchers found that immunotherapy can activate tumor-fighting T cells in nearby lymph nodes, potentially boosting efficacy against solid tumors. The study suggests leaving lymph nodes intact until after immunotherapy could improve treatment outcomes for patients with head and neck cancers.
Researchers have designed a new RNA sensor that can selectively activate synthetic genes in specific cells, opening up possibilities for targeted therapies for cancer and other diseases. The system uses an enzyme that naturally exists in most animal cells to detect and repair mismatches in double-stranded RNA.
A team of researchers developed a novel cancer therapeutic combining antibody fragments with molecularly engineered nanoparticles, permanently eradicating gastric cancer in treated mice. The 'hit and run' drug delivery system targets HER2 proteins associated with gastric cancer.
Researchers discovered that targeting two inflammatory regulators simultaneously can boost T cell expansion and increase antitumor immune activity in models. The findings showed at least 10 times greater T cell expansion when both regulators were knocked out, resulting in improved durability.
UVA researchers discovered a metabolic pathway that can modulate COVID-19 inflammation, lung recovery, and host metabolic health. They suggest a potentially viable therapeutic agent that may be combined with existing anti-viral agents to treat severe COVID-19 in patients with underlying metabolic disease.
A new review paper suggests that selective protection of normal cells from chemotherapy could increase the therapeutic window and improve outcomes for cancer patients. The authors propose using antagonistic drug combinations to kill drug-resistant cancer cells, reducing side effects and improving quality of life.
Researchers at Garvan Institute of Medical Research found that introducing bacteria to a tumor's microenvironment triggers an immune response, activating neutrophils to destroy tumors in animal models. This breakthrough therapy targets neutrophils to improve cancer treatment outcomes.
Dr. Natasha Kekre, a University of Ottawa associate professor and hematologist, has secured millions in funding and published numerous peer-reviewed papers on CAR-T cellular therapies for cancer treatment. Her work has advanced the immunotherapy field in Canada and made her an expert in cancer immunotherapies.
A new study found that less than 4% of people with sickle cell disease have prescriptions for newer FDA-approved pain-relieving drugs, despite their availability. The study also revealed significant gaps in prescription patterns by geographic region and age group, emphasizing the need for education and access to treatment options.
A new cell therapy has demonstrated significant benefits in improving the heart's pumping ability and reducing the risk of cardiovascular death, heart attack, or stroke in patients with chronic heart failure. The therapy, using mesenchymal precursor cells (MPCs), also showed a strong signal in reducing inflammation and improving microv...
CHOP researchers have identified variants of a chaperone molecule that can enhance the loading of peptides across different HLA types, which could be used in cell therapy and immunization applications. The study found that chicken-derived TAPBPR proteins can react with multiple HLA allotypes and stabilize the empty MHC-I groove, boosti...
Researchers at the University of Texas M. D. Anderson Cancer Center have identified CD70 as a novel therapeutic target for eliminating drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer. CD70 targeting strategies showed significant anti-tumor activity, eliminating resistant cells in laboratory models.
Researchers at Harvard's Wyss Institute developed a method to fine-tune CAR-T cell stimulation using artificial antigen-presenting scaffolds. This approach enhances consistency and potency of resulting CAR-T cell products, allowing for better cancer treatment outcomes.
The NCI is funding a $587,000 research grant to improve KRAS treatment resistance in pancreatic cancer. Dr. Andrew Waters aims to develop personalized medicine approaches by studying unique resistance mechanisms.
Researchers highlight CD200's role in regulating immunosuppressive tumor microenvironments and propose alternative strategies for its neutralization. Unbiased genomic- and proteomic-based approaches may help clarify CD200 expression regulation across various human cancers.
A UCF cancer researcher is studying the molecular causes of Alzheimer's disease by examining a protein deficiency in the brain. His research may lead to new targets for therapy and earlier diagnosis. The study focuses on KLF8, a protein important for brain function that has been recorded as deficient in patients with Alzheimer's.
Researchers at Karolinska Institutet have developed a new type of CAR T-cell therapy that effectively attacks and destroys ovarian cancer cells, significantly prolonging the lives of mice with the disease. The treatment has shown promising results in reducing tumor size and curing several mice.
Researchers have discovered that inhibiting conventional signalling pathway by disrupting LCK allows more efficient tumour cell killing, using FYN protein instead. This approach enhances T-cell function and reduces graft-versus-host disease, making CAR-T therapy more accessible to patients.
Researchers at Saint Louis University found that COVID-19 vaccination does not interfere with cancer immunotherapy in previously vaccinated patients. The study supports recommending vaccination to patients with cancer, including those receiving systemic therapies.
Researchers discover gene therapy ophNdi1 that boosts mitochondrial performance in retinal ganglion cells, potentially treating glaucoma and age-related macular degeneration. The therapy shows protective effects in three models of mitochondrial dysfunction.
Researchers developed a cancer-selective therapeutic agent that targets cancer cells' unique acidic pH microenvironment, inducing mitochondrial dysfunction and killing only cancer cells. The agent, Mito-SA, forms charge-shielded nano-assemblies that selectively disassemble in the tumoral environment.
Researchers at Ohio State University Comprehensive Cancer Center have developed a new model system to study human CD8 T-cell dysfunction and found that boosting bone morphogenetic protein 4 (BMP4) while blocking transforming growth factor beta 1 (TGFβ1) preserves the function of chronically stimulated T cells. This approach improved re...
A team of researchers from Korea and USA identified the importance of lipid homeostasis in overcoming brain cancer radioresistance. They found that regulating diacylglycerol kinase B and diacylglycerol acyltransferase 1 could potentially sensitize brain cancer cells to radiotherapy, offering a new treatment strategy.
Researchers from Hospital Universitario 12 de Octubre and Josep Carreras Institute create a cell therapy based on STAb cells for T-Cell Acute Lymphoblastic Leukemia (T-ALL), a rare disease with few treatment options. The new therapy offers an alternative to CAR-T therapies, which have limitations in treating this type of leukemia.
Researchers at University of Texas M. D. Anderson Cancer Center develop a novel mRNA delivery system using extracellular vesicles, which can initiate collagen production in cells and has potential for other mRNA therapies
Researchers discovered that 15-deoxy-prostamide-J2 induces ER stress-mediated apoptosis selectively in tumor cells, reducing melanoma growth. The molecule activates PERK, IP3R, and the mitochondrial permeability transition pore, leading to cell death.
Scientists created Cyborg Cells by combining synthetic polymer networks with bacterial cells, giving them enhanced stress resistance and ability to invade cancer cells. This breakthrough demonstrates the therapeutic potential of Cyborg Cells for various applications.
A preclinical study shows CAR T cell therapy can eliminate residual tumor cells after surgery in mice with breast and pancreatic cancer. The treatment involves applying a gel containing human CAR T cells to surgical wounds, allowing the mice to survive where they would otherwise succumb to tumor recurrence.
A new method utilizes an unnatural sugar to anchor cytokines to T cells, enhancing their functions without systemic side-effects. The approach has shown promise in stimulating the host immune system against tumor cells and inhibiting tumor growth in mice with melanoma.
Researchers at Cedars-Sinai have created a detailed molecular profile of endometriosis, identifying key differences between major subtypes and potential therapeutic targets. The new database will lead to improved care for millions of women suffering from the disease.
In a Phase I clinical trial, afami-cel achieved an objective response rate of 44% in patients with synovial sarcoma and 24% across all cancer types. The therapy demonstrated manageable toxicity and early activity in other cancer types, suggesting potential for solid tumors.
Researchers have discovered a new biomarker that predicts the response to CAR-T cell therapy in patients with diffuse large B cell lymphoma. The biomarker identifies differentiated T cells, which can be removed from leukemia products to improve therapy success rates.
A team of researchers led by Adrian Oblak and Peter Bor-Chian Lin studied the INPP5D gene, which is associated with microglia-specific immune cells. They found that reducing its expression can mitigate Alzheimer's disease pathology, preserving cognitive function in lab models.
Researchers found that MMTV-NeuT/ATTAC mice treated with anti-PD-1 therapy developed increased tumor-associated macrophages, EMT, fibroblast proliferation, and enhanced extracellular matrix. These findings suggest potential therapeutic avenues to enhance PD-1 immune checkpoint sensitivity.
Scientists discover a way to train healthy immune cells to acquire tumor cells' skills for accelerating diabetic wound healing. TAMs-educated macrophages promote cell proliferation, resolve inflammation and orchestrate vasculature.
Researchers at MD Anderson Cancer Center have discovered a novel triple immunotherapy combination targeting checkpoints in T cells and myeloid suppressor cells, improving anti-tumor responses and survival rates in preclinical models of pancreatic cancer. The study found that neutralizing specific immunosuppressive mechanisms dramatical...
A wafer-thin device called NICHE has been developed to treat Type 1 diabetes by delivering islet cells and immunotherapy directly into the body. The device restored healthy glucose levels and eliminated symptoms for over 150 days, avoiding severe adverse effects of anti-rejection therapy.
Researchers at Columbia University School of Engineering and Applied Science have developed a preclinical evaluation pipeline for characterization of bacterial therapies in lung cancer models. They combined bacterial therapies with other modalities of treatment to improve treatment efficacy without any additional toxicity.
The CodeBreaK 100 trial demonstrates meaningful anticancer activity with sotorasib in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer. The results show an objective response rate of 21.1% and a median time-to-response of 1.5 months.
UCSF researchers identified glioma's cellular source of recurrent disease, finding cells shift to mesenchymal, radiation-resistant phenotype in response to standard therapy. Paracrine signals from tumor microenvironment drive this transition through AP1 pathway, leading to therapy resistance and tumor recurrence.
Smidt Heart Institute researchers have identified a way to control the natural 'fight back' response of heart cells against RNA therapies, leading to increased effectiveness. By targeting specific microRNAs, they were able to stabilize the heartbeat and boost gene expression.
Researchers investigate how lung cancers evade the immune system to develop more effective immunotherapy treatments. The study aims to uncover a new way lung cancers disguise themselves from the immune system, potentially leading to improved treatment outcomes.
Researchers from The Mount Sinai Hospital found that talquetamab, a bispecific antibody, was successful in killing multiple myeloma cells in over 70% of patients. This therapy directs the immune system to target cancer cells and has shown promise even for those who have resisted all other treatments.